(NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the enrollment for the second phase of ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise ...

Gov. Kathy Hochul announced plans to build a $430 million New York BioGenesis Park — a cell and gene therapy lab — in Lake ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...

The significance of this is that it brings about the ability to obtain FDA approval for this AAV gene therapy without the need to run a phase 3 study. Even better, it has another positive worth ...

Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...

Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.

Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...